Using these mice, here we demonstrate that an SGLT2 inhibitor canagliflozin (CANA) attenuates the development of hepatocellular carcinoma, as well as hepatic steatosis, inflammation, and fibrosis. This evidence concerns the gene SLC5A2 and fatty liver disease.